Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2019

Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers

Christophe Le Tourneau et al.ESMO 2019Download the poster herePoster Presentation

Published 27 September 2019
Categorized as -others, 2019, 2025, Publication, publication key en, TG4001, TG4001, TG4050

Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results

20190918-Transgene-H1-2019-RESULTS-EN

Published 18 September 2019
Categorized as 2019, Press release

Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050

20190916 PR ANSM TG4050 EN

Published 16 September 2019
Categorized as 2019, Myvac, Press release, TG4050

Transgene Announces Upcoming Investor Meetings

20190829 PR financial Agenda

Published 29 August 2019
Categorized as 2019, Press release

Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer

20190807 – Transgene Update EN

Published 7 August 2019
Categorized as 2019, Pexa-Vec, Press release

Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis

20190802 PHOCUS Interim Analysis US

Published 2 August 2019
Categorized as 2019, Pexa-Vec, Press release

Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases

20190718 – TRANSGENE PR MHRA TG6002

Published 18 July 2019
Categorized as 2019, Press release, TG6002

Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK

20190710 PR MHRA TG4050 EN

Published 10 July 2019
Categorized as 2019, Myvac, Press release, TG4050

Success of Transgene’s €48.7 Million Rights Issue

http://finance.transgene.fr/en/launch.php

Published 2 July 2019
Categorized as 2019, Press release

Transgene Announces the Launch of a Rights Issue

http://finance.transgene.fr/en/launch.php

Published 14 June 2019
Categorized as 2019, Press release

Posts pagination

Newer posts Page 1 Page 2 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu